Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

PEGASYS

PEGINTERFERON ALFA-2A

Standard Dose
180UG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PEGASYS is listed in Drugs@FDA under application 103964 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PEGINTERFERON ALFA-2A Form and strength VIAL; SUBCUTANEOUS - 180UG/VIAL Sponsor Pharmaand GmbH Submission history Latest submission status date: 2023-12-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview PEGASYS is listed in Drugs@FDA under application 103964 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient PEGINTERFERON ALFA-2A Form and strength VIAL; SUBCUTANEOUS - 180UG/VIAL Sponsor Pharmaand GmbH Submission history Latest submission status date: 2023-12-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.